China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has shared an update.
CR Boya Bio-pharmaceutical, a subsidiary of China Resources Pharmaceutical Group Ltd., reported its financial results for the year ended December 31, 2024. The company experienced a notable decline in revenue by 34.58%, yet saw a significant increase in net profit attributable to shareholders by 67.18%, and a remarkable rise in net profit excluding extraordinary gains or losses by 110.77%. Despite the revenue drop, the company’s profitability improved, indicating effective cost management or operational efficiencies.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. operates in the pharmaceutical industry, focusing on the development and distribution of bio-pharmaceutical products. The company holds a significant stake in CR Boya Bio-pharmaceutical, which is listed on the Shenzhen Stock Exchange.
YTD Price Performance: -3.68%
Average Trading Volume: 2,135
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €4.19B
For a thorough assessment of 3320 stock, go to TipRanks’ Stock Analysis page.